HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Summit Therapeutics co-CEO buys $1.46m stock

Created at 4 Jun · 10:45 PM1 source
IN SHORT

Summit Therapeutics co-CEO Zanganeh Mahkam purchased $1.46 million in company stock, according to a recent filing.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

$1.46 millionstock purchase amount

Who's Involved

Zanganeh Mahkam
co-CEO of Summit Therapeutics
Summit Therapeutics
company whose stock was purchased

↳ Why This Matters

Insider buying can signal a belief by company leadership that the stock is undervalued or poised for growth, potentially influencing investor sentiment.

Key facts

  • Summit Therapeutics co-CEO Zanganeh Mahkam bought $1.46 million of company stock.
  • The transaction was disclosed in a recent filing.

Summit Therapeutics co-CEO Zanganeh Mahkam has acquired $1.46 million worth of the company's stock. This significant purchase was made public through a recent regulatory filing, indicating insider confidence in the company's prospects.

Frequently asked questions

Zanganeh Mahkam is the co-CEO of Summit Therapeutics.

Zanganeh Mahkam purchased $1.46 million in Summit Therapeutics stock.

The transaction was disclosed in a recent regulatory filing.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • New Product Summary: Initial Listing of Fifty-Five (55) Single Stock Futures Contracts — Effective July 27, 2026
    27 Jul · 4:32 PM
  • New Product Summary: Initial Listing of Twenty-Two (22) Micro Single Stock Futures Contracts - Effective July 27, 2026
    27 Jul · 4:11 PM
  • Initial Listing of Additional Event Contract Swaps on Pro Golf Tournaments
    9 Jul · 9:41 AM

How It Developed

4 Jun · 10:04 PM
Summit Therapeutics co-CEO Zanganeh Mahkam bought $1.46 million in company stock, according to a recent filing.
Investing.com via PiQSuite

Sources

T1
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stockm.piqsuite.com

Related Stories

Michael Burry Buys Flutter, DraftKings Shares on Prediction Market Threat
8 Jul · 9:51 PM
JPMorgan Hires Michael Flynn to Lead New Small-Cap Banking Business
8 Jul · 3:03 PM
AI and SpaceX Wealth Fuels New Luxury Spending Habits
8 Jul · 10:06 AM
Zhipu AI Shares Rise After Lockup Expiry Amid Investor Support
8 Jul · 8:25 PM
Fast Retailing Q3 profit jumps 45.7%, raises full-year forecast
9 Jul · 6:44 AM